Stay up to date with news and events
Could halting CAG expansions be a new treatment for HD?
October 6, 2023
A recent paper from a group at UMass Chan Medical School, spearheaded by Dr. Daniel O’Reilly and led by Dr. Anastasia Khvorova, used genetic strategies…
Tipping the balance; new insights into HD genetic modifiers
September 1, 2023
Genetic modifiers can influence when HD symptoms begin. Some of these genes encode for different types of molecular machines whose normal job is to repair…
Drug to treat movement symptoms of HD approved by FDA
August 29, 2023
The vast majority of people with Huntington’s disease experience movement symptoms known as chorea. Valbenazine, also known as INGREZZA, has recently been approved by the…
Youthful competitors: young brain cells oust the old
August 8, 2023
When you lose something, an easy solution can be to just replace it. But what if the something you’ve lost are cells in the brain?…
Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
June 23, 2023
On 21st June, both PTC Therapeutics and uniQure shared data from their respective clinical trials, both testing huntingtin-lowering as an approach to treat HD, but…